Health care startups that raised Series B in DACH
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Laza Medical | Pfaffikon | Series B | $160.0M | 2026-11-04 |
| NovaGo Therapeutics | Schlieren | Series B | $29.7M | 2026-08-31 |
| Vaderis Therapeutics | Basel | Series B | $152.0M | 2026-08-11 |
| NVision Quantum Technologies | Ulm | Series B | $38.0M | 2026-05-13 |
| Windward Bio | Basel | Series B | $165.0M | 2026-05-04 |
| Exciva | Heidelberg | Series B | $59.4M | 2026-01-20 |
| GlycoEra | Wädenswil | Series B | $130.0M | 2025-05-27 |
| Clinomic | Aachen | Series B | $25.3M | 2025-04-08 |
8 rows of the CSV in 5 of its 18 columns.
- The 103 health care startups in DACH whose last round is Series B have raised $3.4B in total.
- 11 of them closed their most recent round in the last 12 months, $743.3M combined.
- The largest of those rounds is Windward Bio's $165.0M Series B, dated May 2026.
- The most recent is Laza Medical's $160.0M Series B on 4 November 2026.
- HTGF (High-Tech Gruenderfonds) is an investor in 13 of them, more than any other fund.
- Biotech is the most common other sector, with 53 companies (51%).
- 13% were founded in 2020 or later; the median founding year is 2014.
- The most common team size is 11 to 50 employees (47% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 103| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Laza Medical | Laza Medical produces AI-powered robotic imaging systems for cardiovascular treatments. | Artificial intelligence | Pfaffikon, Switzerland | Series B | $160.0M | 2026-11-04 | $196.0M | Page One Ventures, Unorthodox Ventures, The Capital Partnership | 1 to 10 | 2020 |
| NovaGo Therapeutics | NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke. | Biotech | Schlieren, Switzerland | Series B | $29.7M | 2026-08-31 | $39.7M | Kinled Holding, Pureos Bioventures | 1 to 10 | 2015 |
| Vaderis Therapeutics | Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. | Biotech | Basel, Switzerland | Series B | $152.0M | 2026-08-11 | $170.6M | Medicxi | 11 to 50 | 2019 |
| NVision Quantum Technologies | NVision Quantum Technologies develops quantum-based imaging technology that enhances standard MRI systems. | Biotech | Ulm, Germany | Series B | $38.0M | 2026-05-13 | $155.2M | Entrée Capital, European Commission, Playground Global +2 | 101 to 250 | 2015 |
| Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Basel, Switzerland | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| Exciva | Exciva develops clinical-stage biopharmaceutical therapies for neuropsychiatric symptoms of dementia. | Biotech | Heidelberg, Germany | Series B | $59.4M | 2026-01-20 | $69.8M | Andera Partners, LBBW VC, Cure8 Ventures | 1 to 10 | 2015 |
| GlycoEra | GlycoEra researches and produces extracellular protein degraders for treating autoimmune diseases. | Biotech | Wädenswil, Switzerland | Series B | $130.0M | 2025-05-27 | $179.3M | Sofinnova Partners, Bristol-Myers Squibb, 5AM Ventures +1 | 11 to 50 | 2020 |
| Clinomic | Clinomic is a medical AI company focused on critical care. | Artificial intelligence | Aachen, Germany | Series B | $25.3M | 2025-04-08 | $54.6M | German Federal Ministry of Research, Technology and Space | 51 to 100 | 2019 |
| Noema Pharma | Noema Pharma develops therapies that treat disabling symptoms of brain and nervous system conditions. | Biotech | Basel, Switzerland | Series B | $147.2M | 2024-12-11 | $316.5M | Polaris Partners, Sofinnova Partners, Invus +2 | 11 to 50 | 2019 |
| Aignostics | Aignostics is a company that provides AI-powered pathology diagnostics for drug development and clinical research. | Artificial intelligence | Berlin, Germany | Series B | $34.0M | 2024-10-29 | $54.8M | HTGF (High-Tech Gruenderfonds), IBB Ventures, Wellington Partners +1 | 101 to 250 | 2018 |
| Retinai | RetinAI is a company that simplifies clinic, research, and pharmaceutical workflows to improve healthcare. | Artificial intelligence | Bern, Switzerland | Series B | $7.8M | 2024-10-16 | $16.8M | Venture Kick, Verve Ventures, Matterwave Ventures | 11 to 50 | 2016 |
| CorFlow Therapeutics | CorFlow Therapeutics develops proprietary technologies to diagnose and treat microvascular obstructions. | Biotech | Baar, Switzerland | Series B | $48.5M | 2024-09-10 | $66.1M | Innosuisse, Unorthodox Ventures, Panakes Partners +2 | 11 to 50 | 2016 |
| iOnctura | iOnctura is a clinical-stage biotechnology company developing treatments for cancer. | Biotech | Geneva, Switzerland | Series B | $85.7M | 2024-06-20 | European Innovation Council, M Ventures, VI Partners +2 | 11 to 50 | 2017 | |
| Hemotune | Hemotune develops a therapeutic blood purification platform for treating health conditions. | Biotech | Schlieren, Switzerland | Series B | $15.6M | 2024-03-25 | Venture Kick, Innosuisse, Gebert Rüf Stiftung | 11 to 50 | 2016 | |
| Finanzguru | Finanzguru is an AI-powered financial assistant that helps users manage their accounts and contracts. | Artificial intelligence | Frankfurt, Germany | Series B | $14.2M | 2023-04-04 | Redstone.VC, seed + speed Ventures, Deutsche Bank +2 | 51 to 100 | 2015 | |
| Resolve BioSciences | Resolve BioSciences conducts biotechnology research in molecular cartography. | Biotech | Düsseldorf, Germany | Series B | $71.0M | 2022-10-24 | $95.0M | HTGF (High-Tech Gruenderfonds), EDBI, NRW.BANK +2 | 51 to 100 | 2020 |
| Cardior Pharmaceuticals | Cardior Pharmaceuticals develops medicines and therapies to treat and prevent heart disease. | Biotech | Hanover, Germany | Series B | $75.3M | 2021-08-25 | HTGF (High-Tech Gruenderfonds), EQT Life Sciences, Bristol-Myers Squibb +2 | 11 to 50 | 2016 | |
| Aeris Health | Aeris Health provides smart solutions for monitoring and improving indoor air quality. | Health care | Zug, Switzerland | Series B | $8.5M | 2021-03-01 | $12.8M | PreAngel, Sarona Ventures | 11 to 50 | 2014 |
| Hemovent | Hemovent is an emerging medical device company developing new technology. | Biotech | Aachen, Germany | Series B | $5.2M | 2019-02-14 | $13.5M | KfW, NRW.BANK, TechVision Fund +2 | 1 to 10 | 2013 |
| Amal Therapeutics | Amal Therapeutics SA is a privately held Swiss and German biotech startup spun off from the University of Geneva. | Biotech | Geneva, Switzerland | Series B | $32.6M | 2018-11-12 | HTGF (High-Tech Gruenderfonds), Venture Kick, VI Partners +2 | 11 to 50 | 2012 | |
| Therachon | Therachon is a global biotechnology company developing medicines for rare genetic diseases. | Biotech | Basel, Switzerland | Series B | $60.0M | 2018-08-09 | $100.0M | Bpifrance, New Enterprise Associates, OrbiMed +2 | 1 to 10 | 2014 |
| KB Medical | KB Medical is a Swiss company that designs, develops, and commercializes the AQrate robotic system. | Hardware | Lausanne, Switzerland | Series B | $2.5M | 2016-10-25 | Venture Kick, Foundation for Innovation and Technology (FIT), Kinled Holding | 1 to 10 | 2012 | |
| Cardiorentis | Cardiorentis is a privately owned biopharmaceutical company. | Biotech | Zug, Switzerland | Series B | $60.4M | 2016-01-10 | HealthCare Royalty Partners | 1 to 10 | 2010 | |
| Covagen | Covagen develops protein-based therapeutics for inflammatory diseases and cancer. | Biotech | Schlieren, Switzerland | Series B | $66.1M | 2013-12-09 | Ventech, Novartis Venture Fund, Andera Partners +2 | 11 to 50 | 2007 | |
| Mind-NRG | Mind-NRG develops peptidic neurotrophic factors for psychiatric and neurologic diseases. | Biotech | Geneva, Switzerland | Series B | $7.9M | 2013-09-04 | Index Ventures, Limburgse Reconversie Maatschappij | 1 to 10 | 2010 | |
| Pearltec AG | Pearltec provides placement, positioning, and fixation solutions for patients in research imaging studies. | Health care | Schlieren, Switzerland | Series B | $2.0M | 2012-07-23 | Tugboat | 1 to 10 | 2008 | |
| Okairos | Okairos develops genetic T-cell vaccines, including candidates targeting hepatitis C virus. | Biotech | Basel, Switzerland | Series B | $20.5M | 2010-09-14 | $30.1M | EQT Life Sciences, Versant Ventures, Novartis Venture Fund +2 | 1 to 10 | 2007 |
| ESBATech | ESBATech develops fully human antibody fragments for therapeutic applications using the single-chain antibody framework. | Biotech | Schlieren, Switzerland | Series B | $22.0M | 2008-08-07 | Novartis Venture Fund, VI Partners, SV Health Investors +2 | 51 to 100 | 1998 | |
| Vivendy Therapeutics | Vivendy Therapeutics develops enzyme replacement therapies. | Biotech | Basel, Switzerland | Series B | $30.5M | 2008-06-23 | EQT Life Sciences, BioMedPartners, TVM Capital +1 | 11 to 50 | 2006 | |
| PregLem | PregLem is a Swiss biopharmaceutical company that develops and commercializes new drugs. | Biotech | Geneva, Switzerland | Series B | $32.2M | 2007-12-04 | $58.2M | Sofinnova Partners, Sofinnova Investments, MVM Life Science Partners +1 | 11 to 50 | 2006 |
Table 1. Health care startups that raised Series B in DACH: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 103.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Basel, Switzerland | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| 2 | Laza Medical | Laza Medical produces AI-powered robotic imaging systems for cardiovascular treatments. | Artificial intelligence | Pfaffikon, Switzerland | Series B | $160.0M | 2026-11-04 | $196.0M | Page One Ventures, Unorthodox Ventures, The Capital Partnership | 1 to 10 | 2020 |
| 3 | Vaderis Therapeutics | Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. | Biotech | Basel, Switzerland | Series B | $152.0M | 2026-08-11 | $170.6M | Medicxi | 11 to 50 | 2019 |
| 4 | Exciva | Exciva develops clinical-stage biopharmaceutical therapies for neuropsychiatric symptoms of dementia. | Biotech | Heidelberg, Germany | Series B | $59.4M | 2026-01-20 | $69.8M | Andera Partners, LBBW VC, Cure8 Ventures | 1 to 10 | 2015 |
| 5 | NVision Quantum Technologies | NVision Quantum Technologies develops quantum-based imaging technology that enhances standard MRI systems. | Biotech | Ulm, Germany | Series B | $38.0M | 2026-05-13 | $155.2M | Entrée Capital, European Commission, Playground Global +2 | 101 to 250 | 2015 |
| 6 | NovaGo Therapeutics | NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke. | Biotech | Schlieren, Switzerland | Series B | $29.7M | 2026-08-31 | $39.7M | Kinled Holding, Pureos Bioventures | 1 to 10 | 2015 |
Table 2. Health care startups that raised Series B in DACH: the 6 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | HTGF (High-Tech Gruenderfonds) | Venture capital firm | Bonn, Germany | 13 | 13% | ||
| 2 | Venture Kick | Startup incubator | Schlieren, Switzerland | 8 | 8% | ||
| 3 | Andera Partners | Private equity firm | Paris, France | 4 | 4% | 1 | Exciva |
| 4 | Boehringer Ingelheim Venture Fund | Corporate venture arm | Ingelheim Am Rhein, Germany | 4 | 4% | ||
| 5 | Verve Ventures | Venture capital firm | Zug, Switzerland | 4 | 4% | ||
| 6 | Innosuisse | Government investment office | Berne, Switzerland | 4 | 4% | ||
| 7 | VI Partners | Venture capital firm | Altendorf, Switzerland | 4 | 4% | ||
| 8 | NRW.BANK | Government investment office | Düsseldorf, Germany | 4 | 4% | ||
| 9 | German Federal Ministry of Research, Technology and Space | Government investment office | Bonn, Germany | 3 | 3% | 1 | NVision Quantum Technologies |
| 10 | Sofinnova Partners | Venture capital firm | Paris, France | 3 | 3% | ||
| 11 | Forbion Capital Partners | Private equity firm | Naarden, The Netherlands | 3 | 3% | ||
| 12 | EQT Life Sciences | Private equity firm | Amsterdam, The Netherlands | 3 | 3% | ||
| 13 | BioMedPartners | Venture capital firm | Basel, Switzerland | 3 | 3% | ||
| 14 | Novartis Venture Fund | Corporate venture arm | Basel, Switzerland | 3 | 3% | ||
| 15 | Unorthodox Ventures | Family office | Austin, United States | 2 | 2% | 1 | Laza Medical |
Table 3. Health care startups that raised Series B in DACH: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
Table 4. Health care startups that raised Series B in DACH by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 103 | 100% | $20.0M |
Table 5. Health care startups that raised Series B in DACH by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| Switzerland | 51 | 50% |
| Germany | 50 | 49% |
| Austria | 2 | 2% |
Table 6. Health care startups that raised Series B in DACH by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Berlin | 14 | 14% |
| Basel | 8 | 8% |
| Munich | 8 | 8% |
| Zürich | 6 | 6% |
| Schlieren | 5 | 5% |
| Lausanne | 4 | 4% |
| Geneva | 4 | 4% |
| Frankfurt | 4 | 4% |
| Heidelberg | 3 | 3% |
| Zug | 3 | 3% |
| Neuchâtel | 2 | 2% |
| Aachen | 2 | 2% |
Table 7. Health care startups that raised Series B in DACH by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 9% | $160.0M |
| August 2026 | 2 | 18% | $181.7M |
| July 2026 | 2 | 18% | $38.0M |
| June 2026 | 1 | 9% | $50.0M |
| May 2026 | 3 | 27% | $236.6M |
| April 2026 | 1 | 9% | $17.6M |
| January 2026 | 1 | 9% | $59.4M |
Table 8. Health care startups that raised Series B in DACH: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 11 | 11% | $743.3M |
| 2025 | 6 | 6% | $282.8M |
| 2024 | 10 | 10% | $511.2M |
| 2023 | 3 | 3% | $19.3M |
| 2022 | 11 | 11% | $256.7M |
| 2021 | 10 | 10% | $342.3M |
Table 9. Health care startups that raised Series B in DACH by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 1 | 1% |
| 2020 to 2022 | 12 | 12% |
| 2015 to 2019 | 35 | 34% |
| 2010 to 2014 | 28 | 27% |
| Before 2010 | 27 | 26% |
Table 10. Health care startups that raised Series B in DACH by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 25 | 24% |
| 11 to 50 | 48 | 47% |
| 51 to 100 | 15 | 15% |
| 101 to 250 | 10 | 10% |
| 251 to 500 | 4 | 4% |
| 1,001 to 5,000 | 1 | 1% |
Table 11. Health care startups that raised Series B in DACH by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Health care is one of its sectors and its most recent funding round is Series B and its headquarters is in DACH. On 16 November 2026 that is 103 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 103 rows: 15 have no round amount, 0 no city and 38 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many health care startups in DACH whose last round is Series B are on the list?
- 103, in the file dated 16 November 2026. 11 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 103 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.